Adenosine receptor protein changes in guinea pigs with form deprivation myopia
Adenosine receptor protein changes in guinea pigs with form deprivation myopia
复制标题
DOI：
10.1111/j.1755-3768.2009.01559.x
复制
发表时间：
2010-11-01
影响因子：
3.4
通讯作者：
Ge, Jian
中科院分区：
文献类型：
--
作者：
Cui, Dongmei;Trier, Klaus;Ge, Jian
目的：最近的研究结果表明，用非选择性腺苷拮抗剂7-甲基黄嘌呤（7-MX）治疗可以减少豚鼠形式剥夺性近视（FDM）的发展。本研究的目的是鉴定豚鼠眼壁中腺苷受体（AdoRs）的存在，并确定它们在形态剥夺期间可能发生的变化。方法：对3周龄豚鼠进行单眼透明晶状体诱导FDM。21天后，从眼后壁取标本，用免疫荧光共聚焦显微镜检测AdoRA1、AdoRA2A、AdoRA2B和AdoRA3蛋白的存在。采用Western blot方法定量测定视网膜、脉络膜和巩膜样品中的AdoRs。结果：4种AdoR亚型均在豚鼠眼后壁表达，但AdoRA3表达较弱。诱导近视21天后，我们观察到FDM眼视网膜中AdoRA1蛋白表达显著降低（- 25.5%），AdoRA2B蛋白表达显著升高（+ 66.7%）。结论：AdoRs所有亚型均在豚鼠视网膜、脉络膜和巩膜中表达，并可能在调节眼睛生长中发挥作用。形式剥夺过程中AdoR表达模式的改变证实了以AdoRs为目标的药物干预可能会减少近视的进展。
Purpose:Recent results have shown that treatment with the non-selective adenosine antagonist 7-methylxanthine (7-MX) reduces the development of form deprivation myopia (FDM) in guinea pigs. The aims of this study were to identify the presence of adenosine receptors (AdoRs) in the eye wall of the guinea pig and to determine their possible changes during form deprivation.Methods:Three-week-old guinea pigs were monocularly treated with a translucent lens to induce FDM. After 21 days, samples were taken from the posterior eye wall and examined with immunofluorescence confocal microscopy for the presence of AdoRA1, AdoRA2A, AdoRA2B and AdoRA3 proteins. Western blot analysis was used to quantitate AdoRs in samples from the retina, choroids and sclera.Results:All four subtypes of AdoR were expressed in the posterior wall of the guinea pig eye, although AdoRA3 only weakly. Twenty-one days after the induction of myopia, we observed a significant decrease in protein expression for AdoRA1 (- 25.5%) and an increase in protein expression for AdoRA2B (+ 66.7%) in the retina of FDM eyes.Conclusions:AdoRs of all subtypes are expressed in the retina, choroids and sclera in guinea pigs and may play a role in the regulation of eye growth. The changed pattern of AdoR expression during form deprivation confirms that pharmaceutical intervention targeting AdoRs may reduce myopia progression.